Nano cap SELLAS Life Sciences (NASDAQ:SLS) is up 11% premarket on increased volume in reaction to its announcement that
it has finalized the design and plan for a pivotal Phase 3 clinical
trial evaluating the combination of nelipepimut-S and trastuzumab
(marketed as Herceptin by Roche), for the adjuvant treatment of patients
with triple-negative breast cancer who have received standard-of-care
therapy.
If successful, the data may support a U.S. marketing application.
https://seekingalpha.com/news/3542211-sellas-life-sciences-up-11-premarket-on-advancement-of-nelipepimut-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.